Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
61.581,98
1,13%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verona Pharma Plc (VRNA) Verona Pharma Plc (VRNA) Notizie

VRNA

Verona Pharma (VRNA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VRNA
DataOraFonteTitoloSimboloCompagnia
26/06/202422:57GlobeNewswire Inc.Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)NASDAQ:VRNAVerona Pharma Plc
10/05/202415:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRNAVerona Pharma Plc
10/05/202414:53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRNAVerona Pharma Plc
09/05/202413:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRNAVerona Pharma Plc
09/05/202413:15GlobeNewswire Inc.Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
09/05/202413:00GlobeNewswire Inc.Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSNASDAQ:VRNAVerona Pharma Plc
02/05/202408:00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024NASDAQ:VRNAVerona Pharma Plc
25/04/202408:00GlobeNewswire Inc.Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
08/03/202422:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VRNAVerona Pharma Plc
08/03/202403:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
04/03/202408:00GlobeNewswire Inc.Andrew Fisher Joins Verona Pharma as General CounselNASDAQ:VRNAVerona Pharma Plc
29/02/202415:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VRNAVerona Pharma Plc
29/02/202408:00GlobeNewswire Inc.Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
15/02/202408:00GlobeNewswire Inc.Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
06/02/202400:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRNAVerona Pharma Plc
05/02/202422:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRNAVerona Pharma Plc
01/02/202408:00GlobeNewswire Inc.Michael Austwick Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/01/202408:00GlobeNewswire Inc.Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRNAVerona Pharma Plc
02/01/202408:00GlobeNewswire Inc.Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalNASDAQ:VRNAVerona Pharma Plc
17/11/202308:00GlobeNewswire Inc.Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardNASDAQ:VRNAVerona Pharma Plc
08/11/202308:00GlobeNewswire Inc.Verona Pharma Announces November 2023 Investor Conference ParticipationNASDAQ:VRNAVerona Pharma Plc
02/11/202308:04GlobeNewswire Inc.Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
19/10/202308:00GlobeNewswire Inc.Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
06/10/202308:00GlobeNewswire Inc.Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023NASDAQ:VRNAVerona Pharma Plc
03/10/202308:00GlobeNewswire Inc.Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023NASDAQ:VRNAVerona Pharma Plc
11/09/202308:00GlobeNewswire Inc.Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDNASDAQ:VRNAVerona Pharma Plc
06/09/202308:00GlobeNewswire Inc.Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023NASDAQ:VRNAVerona Pharma Plc
31/08/202308:00GlobeNewswire Inc.Christina Ackermann Joins Verona Pharma as Non-Executive DirectorNASDAQ:VRNAVerona Pharma Plc
03/08/202308:00GlobeNewswire Inc.Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRNAVerona Pharma Plc
26/07/202308:00GlobeNewswire Inc.Verona Pharma to Present at 43rd Annual Canaccord Growth ConferenceNASDAQ:VRNAVerona Pharma Plc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VRNA

La tua Cronologia

BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
SPM
Saipem
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
CPR
Davide Campari
BIT
TRN
Terna Trasmissione Elett...
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
SRG
Snam
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network